Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes
Jacqueline Bayliss, Geraldine J Ooi, William De Nardo, Yazmin Johari Halim Shah, Magdalene K Montgomery, Catriona McLean, William Kemp, Stuart K Roberts, Wendy A Brown, Paul R Burton, Matthew J Watt
FRONTIERS IN ENDOCRINOLOGY | FRONTIERS MEDIA SA | Published : 2021
Ectodysplasin A (EDA) was recently identified as a liver-secreted protein that is increased in the liver and plasma of obese mice and causes skeletal muscle insulin resistance. We assessed if liver and plasma EDA is associated with worsening non-alcoholic fatty liver disease (NAFLD) in obese patients and evaluated plasma EDA as a biomarker for NAFLD. Using a cross-sectional study in a public hospital, patients with a body mass index >30 kg/m2 (n=152) underwent liver biopsy for histopathology assessment and fasting liver EDA mRNA. Fasting plasma EDA levels were also assessed. Non-alcoholic fatty liver (NAFL) was defined as >5% hepatic steatosis and nonalcoholic steatohepatitis (NASH) as NAFLD..View full abstract
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by NHMRC
These studies were supported by the National Health and Medical Research Council of Australia (NHMRC, APP1162511). MM is supported by Research Fellowships from the NHMRC (APP1143224). WN is supported by a Melbourne Research Scholarship (University of Melbourne).